CoChat

Adverse effects of Z-drugs for sleep disturbance in people living with dementia: a population-based cohort study

Open access

The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.

Abstract

Background: Sleep disturbance is common in dementia and often treated with Z-drugs (zopiclone, zaleplon, and zolpidem). While some observational studies suggest that Z-drugs are associated with adverse events such as falls and fracture risks in older people, this has not been studied in dementia. Methods: We used data from 27,090 patients diagnosed with dementia between January 2000 and March 2016 from the Clinical Practice Research Datalink linked to Hospital Episodes Statistics data in England. We compared adverse events for 3532 patients newly prescribed Z-drugs by time-varying dosage to (1) 1833 non-sedative-users with sleep disturbance; (2) 10,214 non-sedative-users with proximal GP consultation matched on age, sex, and antipsychotic use; and (3) 5172 patients newly prescribed benzodiazepines. We defined higher dose Z-drugs and benzodiazepines as prescriptions equivalent to ≥ 7.5 mg zopiclone or > 5 mg diazepam daily. Cox regression was used to estimate hazard ratios (HRs) for incident fracture, hip fracture, fall, mortality, acute bacterial infection, ischaemic stroke/transient ischaemic attack, and venous thromboembolism over a 2-year follow-up, adjusted for demographic- and health-related covariates. Results: The mean (SD) age of patients was 83 (7.7) years, and 16,802 (62%) were women. Of 3532 patients prescribed Z-drugs, 584 (17%) were initiated at higher doses. For patients prescribed higher dose Z-drugs relative to non-users with sleep disturbance, the HRs (95% confidence interval) for fractures, hip fractures, falls, and ischaemic stroke were 1.67 (1.13–2.46), 1.96 (1.16–3.31), 1.33 (1.06–1.66), and 1.88 (1.14–3.10), respectively. We observed similar associations when compared to non-sedative-users with proximal GP consultation. Minimal or inconsistent excess risks were observed at ≤ 3.75 mg zopiclone or equivalent daily, and for mortality, infection, and venous thromboembolism. We observed no differences in adverse events for Z-drugs compared to benzodiazepines, except lower mortality rates with Z-drugs (HR [95% confidence interval] of 0.73 [0.64–0.83]). Conclusions: Higher dose Z-drug use in dementia is associated with increased fracture and stroke risks, similar or greater to that for higher dose benzodiazepines. Higher dose Z-drugs should be avoided, if possible, in people living with dementia, and non-pharmacological alternatives preferentially considered. Prescriptions for higher dose Z-drugs in dementia should be regularly reviewed. Trial registration: ENCePP e-register of studies,EUPAS18006

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12916-020-01821-5

Cites

67 of 67 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 67 references

Research works printed but not linked: 1

  1. Patel V. Deaths registered in England and Wales: 2017. London: Office for National Statistics; 2018.

Cited by

See all 73

Metadata

Authors
Richardson, K., Loke, Y. K., Fox, C., Maidment, I., Howard, R., Steel, N., Arthur, A., Boyd, P. J., Aldus, C., Ballard, C., & Savva, G. M.
Affiliations
  • University of East Anglia (GB)
  • Aston University (GB)
  • University College London (GB)
  • University of Exeter (GB)
Corresponding author
Richardson, Kathryn
Venue
BMC Medicine
Published
2020-11-24
Volume
18
Issue
1
Pages
351-351
ISSN
1741-7015 (ISSN-L)
OpenAlex
W3097629622
Cited by
73
References
67
Citations by year
2026: 18 · 2025: 17 · 2024: 13 · 2023: 8 · 2022: 12 · 2021: 4 · 2020: 1
FWCI
3.28
Type
journal article
Language
en
Open access
Licence
Locations
  • BMC Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Aston Publications Explorer (Aston University) (acceptedVersion)
  • UEA Digital Repository (University of East Anglia) (acceptedVersion)
  • UCL Discovery (University College London) (submittedVersion)
  • Figshare (submittedVersion, cc-by)
  • Open Research Exeter (University of Exeter) (submittedVersion, cc-by)
Funders
  • Health Technology Assessment Programme (14/221/02)
  • National Institute for Health Research
Topics
  • Health Sciences › Medicine › Geriatrics and Gerontology › Pharmaceutical Practices and Patient Outcomes
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Sleep and related disorders
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords
Z-drugs, zopiclone, zaleplon, zolpidem, dementia, sleep disorders, benzodiazepines, adverse drug reactions, falls, hip fracture, fracture risk, ischemic stroke, venous thromboembolism, mortality, dose-response relationship, older adults, Clinical Practice Research Datalink, Hospital Episode Statistics
MeSH terms
Zolpidem, Acetamides, Aged, 80 and over, Dementia, Female, Humans, Male, Piperazines, Pyrimidines, Sleep Wake Disorders, Cohort Studies, Azabicyclo Compounds

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Adverse effects of Z-drugs for sleep disturbance in people living with dementia: a population-based cohort study. https://app.cochat.ai/papers/10.1186/s12916-020-01821-5
The paper
Richardson, K., Loke, Y. K., Fox, C., Maidment, I., Howard, R., Steel, N., Arthur, A., Boyd, P. J., Aldus, C., Ballard, C., & Savva, G. M. (2020). Adverse effects of Z-drugs for sleep disturbance in people living with dementia: a population-based cohort study. BMC Medicine. https://doi.org/10.1186/s12916-020-01821-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.